Valuation: Nanobiotix

Market Cap 1.48B 1.69B 1.4B 1.28B 2.39B 162B 2.4B 16.75B 6.49B 82.68B 6.34B 6.2B 266B P/E 2026 *
-47.8x
P/E 2027 * -117x
Enterprise Value 1.52B 1.73B 1.43B 1.31B 2.45B 166B 2.46B 17.16B 6.65B 84.71B 6.5B 6.36B 272B EV / Sales 2026 *
51.6x
EV / Sales 2027 * 35.1x
Free-Float
88.26%
Yield 2026 *
-
Yield 2027 * -
1 day+4.37%
1 week-2.34%
Current month-15.97%
1 month-15.82%
3 months-6.18%
6 months+7.80%
Current year+49.54%
1 week 27.12
Extreme 27.12
31.46
1 month 27.12
Extreme 27.12
38.9
Current year 16.66
Extreme 16.66
47.66
1 year 12.92
Extreme 12.92
47.66
3 years 2.62
Extreme 2.62
47.66
5 years 1.61
Extreme 1.612
47.66
10 years 1.61
Extreme 1.612
47.66
Manager TitleAgeSince
Chief Executive Officer 55 16/11/2009
Director of Finance/CFO 54 01/06/2021
Chief Tech/Sci/R&D Officer 68 05/09/2023
Director TitleAgeSince
Director/Board Member 76 23/06/2011
Director/Board Member 65 01/01/2014
Director/Board Member 57 18/06/2014
Date Insider Type Main position Quantity % Market Cap. Importance
7/17/26 A Buy

Chairman

598 0.0012%
7/17/26 A Buy

Chairman

598 0.0012%
7/16/26 A Buy

Chairman

6,114 0.0121%
Change 5-day change 1-year change 3-year change Capi.($)
+4.37%-2.34%+121.58%+257.35% 1.69B
-0.14%+4.33%+9.00%+31.64% 47.97B
-1.69%+1.48%+50.57%+34.53% 44.5B
+2.56%+7.34%+366.69%+608.26% 43.93B
+0.24%+2.85%+10.67%+94.47% 41.03B
-0.62%-1.11%+4.65%+48.91% 29.85B
-0.28%+1.07%+24.58%+155.58% 17.27B
+3.37%+9.21%+8.32% - 15.34B
-0.46%+1.20%+26.90%+42.21% 15.3B
-2.21%-4.70% - - 14.82B
Average +0.51%+1.75%+69.22%+159.12% 27.17B
Weighted average by Cap. +0.13%+2.62%+79.95%+160.96%

Financials

2026 *2027 *
Net sales 29.44M 33.55M 27.81M 25.34M 47.44M 3.22B 47.77M 333M 129M 1.64B 126M 123M 5.28B 44.36M 50.56M 41.9M 38.18M 71.48M 4.85B 71.99M 501M 194M 2.48B 190M 186M 7.96B
Net income -26.47M -30.16M -25M -22.78M -42.64M -2.89B -42.95M -299M -116M -1.48B -113M -111M -4.75B -21.29K -24.26K -20.11K -18.32K -34.3K -2.33M -34.55K -241K -93.2K -1.19M -91.09K -89.12K -3.82M
Net Debt 36.43M 41.52M 34.41M 31.36M 58.7M 3.98B 59.12M 412M 159M 2.03B 156M 153M 6.53B 74.7M 85.13M 70.55M 64.29M 120M 8.16B 121M 844M 327M 4.17B 320M 313M 13.4B
Logo Nanobiotix
Nanobiotix is a pioneer and leader in nanomedicine that has developed a revolutionary approach to the treatment of cancer. The company focuses its effort on the development of its products portfolio entirely patented, NanoXray, innovation based on the physical mode of action of nanoparticles that, under the action of radiation, allow maximizing the absorption of X-rays inside the cancer cells without increasing the dose received by the surrounding healthy tissue. NanoXray products are compatible with standard radiotherapy treatments and are intended to potentially treat a wide variety of cancers via multiple routes of administration. The company's resources are primarily devoted to the development of its lead product candidate: JNJ-1900 (NBTXR3), which is the product of its proprietary oncology platform and has already achieved market authorization in Europe for the treatment of patients with soft tissue sarcoma under.
Employees
100
Date Price Change Volume
25/09/26 €29.16 +4.37% 196,590
24/09/26 €27.94 -7.61% 143,062
23/09/26 €30.24 +0.13% 110,443
22/09/26 €30.20 +1.82% 75,139
21/09/26 €29.66 -0.67% 151,981
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
29.16EUR
Average target price
52.20EUR
Spread / Average Target
+79.01%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NANO Stock